RecruitMe Clinical Trial

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
AURORA Study: Iloprost for Subjects with Systemic Sclerosis (SSc-Raynaud's Phenomenon)
Sponsor:Eicos Sciences, Inc.
Enrolling:Male and Female Patients
Study Length:35 Days
Clinic Visits:7
Minimum Age:18 years old
IRB Number:AAAS5867
U.S. Government ID:NCT04040322
Contact: Rachel Broderick: 212-342-2713 / rb3173@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find out whether a drug called iloprost is safe to use in people with systemic sclerosis (SSc) (Raynaud's phenomenon), and whether it may help decrease symptomatic digital ischemic episodes (episodes in the fingers).

Do You Qualify?
Have you been diagnosed with systemic sclerosis (scleroderma)?YesNo
Do you experience Raynaud's phenomenon?YesNo
Submit
Cancel
Investigator
Elana Bernstein, MD, MSc
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rachel Broderick
Email: rb3173@cumc.columbia.edu
Phone: 212-342-2713